Renal Implications of Resistant Hypertension is organized by Med-IQ.
Initial Release Date: February 28, 2019
Expiration Date: February 27, 2020
This activity is intended for community nephrologists.
Med-IQ designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This brief activity discusses the definition of resistant hypertension (RH) as well as ways to evaluate and assess the condition. In addition, faculty provide insights on current management strategies for patients with both RH and chronic kidney disease.
Statement of Need:
Hypertension remains the single most important modifiable risk factor for cardiovascular disease (CVD), stroke, disability, and death. Adults who have persistently elevated BP despite the use of 3 antihypertensive medications of different classes are considered to have resistant hypertension (RH). RH is a particularly important clinical comorbidity in those with chronic kidney disease (CKD). Individuals with CKD commonly have hypertension and an associated increased risk of CVD, and those with RH have an elevated risk of developing end-stage renal disease and other CVD events. Given the clinical implications of CKD in RH, it is important to review key aspects of RH management in this patient population. Thus, in this publication, we review the evaluation and assessment of RH in those with CKD as well as pharmacologic-, lifestyle-, and device-based strategies to address the condition and improve patient outcomes.
Upon completion, participants should be able to:
• Understand the risks and benefits of available treatments for resistant hypertension in patients with CKD
Renal Medicine Disease and Hypertension